Lakefront Biotherapeutics NV (LKFT) revenue
Lakefront Biotherapeutics NV (LKFT) reported revenue of €1.11B in fiscal 2025 (the year ended December 31, 2025). That is 303.5% higher than the €275.65M of fiscal 2024. Figures as of 18 Nov 2026, 11:34 UTC, from Yahoo Finance.
Key facts
- Revenue, fiscal 2025
- €1.11B
- Change on fiscal 2024
- +303.5%
- Highest on record
- €1.11Bfiscal 2025
- Lowest on record
- €239.72Mfiscal 2023
- Fiscal years on record
- 42022–2025
Figures as of . Statements from Yahoo Finance. Amounts are in EUR. Figures, not advice.
Lakefront Biotherapeutics NV revenue, in more detail
Across the 4 fiscal years on record (2022–2025), the highest was €1.11B in fiscal 2025 and the lowest €239.72M in fiscal 2023.
Revenue by fiscal year
Lakefront Biotherapeutics NV revenue, year by year
| Fiscal year | Revenue | Change | Year ended |
|---|---|---|---|
| 2025 | €1.11B | 303.5% up | |
| 2024 | €275.65M | 15.0% up | |
| 2023 | €239.72M | 0.6% down | |
| 2022 | €241.25M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.
How to read it
Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.
Lakefront Biotherapeutics NV, figure by figure
- Lakefront Biotherapeutics NV market cap
- Lakefront Biotherapeutics NV earnings
- Lakefront Biotherapeutics NV earnings per share (EPS)
- Lakefront Biotherapeutics NV P/E ratio
- Lakefront Biotherapeutics NV P/S ratio
- Lakefront Biotherapeutics NV P/B ratio
- Lakefront Biotherapeutics NV free cash flow
- Lakefront Biotherapeutics NV operating margin
- Lakefront Biotherapeutics NV dividend
- Lakefront Biotherapeutics NV shares outstanding
- Lakefront Biotherapeutics NV total debt
- Lakefront Biotherapeutics NV cash on hand
- Lakefront Biotherapeutics NV total assets
- Lakefront Biotherapeutics NV return on equity (ROE)
- Lakefront Biotherapeutics NV return on invested capital (ROIC)
Lakefront Biotherapeutics NV (LKFT) overview: price, valuation and scorecard
Lakefront Biotherapeutics NV revenue: questions and answers
What is Lakefront Biotherapeutics NV's revenue?
Lakefront Biotherapeutics NV (LKFT) reported revenue of €1.11B in fiscal 2025 (the year ended December 31, 2025). That is 303.5% higher than the €275.65M of fiscal 2024.
What are the highest and lowest revenue figures on record for Lakefront Biotherapeutics NV?
Across the 4 fiscal years on record (2022–2025), the highest was €1.11B in fiscal 2025 and the lowest €239.72M in fiscal 2023.
How is Lakefront Biotherapeutics NV's revenue calculated?
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Lakefront Biotherapeutics NV it is on record here for 4 fiscal years, 2022 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: revenue
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Lakefront Biotherapeutics NV (LKFT) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/LKFT/revenue
Underlying data: Yahoo Finance.